Physician

David H Silber, MD

According to 2025 Medicare claims, David Silber, MD (NPI: 1336197268) practices advanced heart failure and transplant cardiology in the Harrisburg-Carlisle, PA market, with the plurality of this provider's patient population coming from Dauphin, PA. This provider's primary affiliated billing organization is THE MILTON S HERSHEY MEDICAL CENTER PHYSICIANS GROUP (NPI: 1881669257; TIN: 251857035) and primary practice location at 17033-2360.

Silber's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 154 traditional Medicare patients, billed 409 HCPCS/CPT codes, and received $24,338 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 2,310 prescription claims across 221 beneficiaries totaling $2,594,288 in drug costs, led by Tyvaso Dpi (Treprostinil). DME data shows 316 claims. Open Payments data shows 3 records totaling $210. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $34,739 to $24,338. In contrast, Part D prescription costs have risen steadily, from $1,204,686 to $2,594,288. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $5,389 and ending at $3,696.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	247	641	$34,739
2016	266	797	$44,759
2017	229	742	$43,596
2018	203	647	$37,440
2019	214	706	$43,511
2020	171	409	$22,340
2021	174	525	$31,133
2022	183	485	$29,856
2023	163	478	$30,398
2024	154	409	$24,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	189	1,889	$1,204,686
2016	247	2,453	$1,469,850
2017	248	2,579	$1,701,649
2018	242	2,240	$1,665,349
2019	228	1,967	$1,780,465
2020	182	1,745	$1,559,716
2021	188	1,809	$1,779,158
2022	213	2,000	$1,721,901
2023	221	2,165	$2,519,912
2024	221	2,310	$2,594,288

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	180	$332,889
2016	11	351	$321,846
2017	43	573	$456,228
2018	43	423	$392,759
2019	35	493	$423,393
2020	N/R	217	$266,319
2021	N/R	137	$267,321
2022	N/R	157	$263,497
2023	N/R	164	$2,655
2024	22	316	$120,955

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	16	17	$99
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	103	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	40	194	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	44	50	$41
93018	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician	11	11	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tyvaso Dpi	Treprostinil	24	672	$618,514
Ambrisentan	Ambrisentan	71	2,610	$562,784
Opsumit	Macitentan	36	1,080	$453,159
Entresto	Sacubitril/Valsartan	198	11,573	$248,925
Adempas	Riociguat	13	390	$180,632

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J3285	Injection, treprostinil, 1 mg	N	N/R	12	$113,577
K0455	Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)	Y	N/R	11	$2,649
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	62	$1,148
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	95	$1,116
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	11	93	$1,041

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$210	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David H. Silber, MD?

Tedicare shows public-source Medicare data for David H. Silber, MD (NPI 1336197268), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David H. Silber, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David H. Silber, MD?

David H. Silber, MD is linked to THE MILTON S HERSHEY MEDICAL CENTER PHYSICIANS GROUP (billing NPI 1881669257) in the available physician profile data.

Does David H. Silber, MD have Open Payments data?

David H. Silber, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.